p53 Antibody (2B2.68): sc-71817
- p53 Antibody (2B2.68) is a mouse monoclonal IgG2a κ, cited in 23 publications, provided at 200 µg/ml
- N-terminal epitope mapping between amino acid residues 11-25 of p53 of human origin
- recommended for detection of wild type and mutant p53 under denaturing and non-denaturing conditions of human origin by WB, IP, IF, IHC(P) and FCM
- available conjugated to agarose for IP; to HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to TRITC for IF, IHC(P) and FCM
- TransCruz reagent for Gel Supershift and ChIP applications (sc-71817 X, 200 µg/0.1 ml)
- See p53 (DO-1): sc-126 for p53 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG2a BP-HRP are the preferred secondary detection reagents for p53 Antibody (2B2.68) for WB and IHC(P) applications. These reagents are now offered in bundles with p53 Antibody (2B2.68) (see ordering information below).
QUICK LINKS
SEE ALSO...
p53 Antibody (2B2.68) is an IgG2a kappa light chain mouse monoclonal antibody that binds to an N-terminal epitope between amino acid residues 11-25 of human p53, detecting both wild-type and mutant forms. p53 (2B2.68) monoclonal antibody is available for multiple applications such as immunoprecipitation, western blotting, immunohistochemistry, ELISA, flow cytometry, and immunofluorescence. The p53 protein, is a crucial tumor suppressor that plays a key role in maintaining DNA integrity. Encoded by the TP53 gene, p53 acts as a transcription factor, regulating essential cellular processes like DNA repair, cell cycle arrest, apoptosis, and cellular senescence. When cells experience stress or DNA damage, p53 activates and halts the cell cycle at critical checkpoints (G1/S or G2/M) to allow DNA repair. If the damage is irreparable, p53 initiates apoptosis, preventing the spread of genetically abnormal cells and reducing the risk of tumor development. p53 regulation occurs through post-translational modifications such as phosphorylation and acetylation. Phosphorylation at serine residues like Ser6, Ser15, and Ser46, by kinases such as ATM, ATR, and Chk2, enhances p53′s stability and ability to bind DNA. Acetylation by p300 and CBP stabilizes p53 further, while deacetylation by proteins like SIRT1 adjusts its function during cellular aging or in response to DNA damage. In cancer research, antibodies targeting p53 help study its role in disease. By using the p53 monoclonal antibody (2B2.68), researchers can assess p53 expression, post-translational modifications, and its localization in tissues. Given that p53 mutations are common in various cancers, these studies are critical for understanding tumor suppression mechanisms and developing targeted therapeutic strategies in the p53 pathway.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
p53 Antibody (2B2.68) References:
- Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. | Blaydes, JP., et al. 2001. J Biol Chem. 276: 4699-708. PMID: 11078726
- Stimulation of autophagy by the p53 target gene Sestrin2. | Maiuri, MC., et al. 2009. Cell Cycle. 8: 1571-6. PMID: 19377293
- Functions of p53 in metabolism and invasion. | Vousden, KH. 2009. Biochem Soc Trans. 37: 511-7. PMID: 19442244
- Transactivation by temperature-dependent p53 mutants in yeast and human cells. | Slovackova, J., et al. 2010. Cell Cycle. 9: 2141-8. PMID: 20505364
- Sliding of p53 along DNA can be modulated by its oligomeric state and by cross-talks between its constituent domains. | Khazanov, N. and Levy, Y. 2011. J Mol Biol. 408: 335-55. PMID: 21338609
- Morphofunctional Differences of Micronuclei in Cultures of Human p53-Positive and p53-Negative Tumor Cells. | Sutyagina, OI. and Kisurina-Evgenieva, OP. 2019. Bull Exp Biol Med. 167: 813-817. PMID: 31656006
- Ultrasound-triggered reactive oxygen species effector nanoamplifier for enhanced combination therapy of mutant p53 tumors. | Wang, X., et al. 2022. Colloids Surf B Biointerfaces. 215: 112489. PMID: 35395477
- Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. | Subler, MA., et al. 1994. Oncogene. 9: 1351-9. PMID: 8152795
- TP53 tumor-suppressor gene and human carcinogenesis. | Basset-Séguin, N., et al. 1993. Exp Dermatol. 2: 99-105. PMID: 8162331
- Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. | Komarova, EA., et al. 1997. Cancer Res. 57: 5217-20. PMID: 9393737
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
p53 Antibody (2B2.68) | sc-71817 | 200 µg/ml | $322.00 | |||
p53 Antibody (2B2.68): m-IgG Fc BP-HRP Bundle | sc-539414 | 200 µg Ab; 10 µg BP | $361.00 | |||
p53 Antibody (2B2.68): m-IgG2a BP-HRP Bundle | sc-546699 | 200 µg Ab; 10 µg BP | $361.00 | |||
p53 Antibody (2B2.68) AC | sc-71817 AC | 500 µg/ml, 25% agarose | $424.00 | |||
p53 Antibody (2B2.68) FITC | sc-71817 FITC | 200 µg/ml | $336.00 | |||
p53 Antibody (2B2.68) HRP | sc-71817 HRP | 200 µg/ml | $322.00 | |||
p53 Antibody (2B2.68) PE | sc-71817 PE | 200 µg/ml | $349.00 | |||
p53 Antibody (2B2.68) TRITC | sc-71817 TRITC | 200 µg/ml | $326.00 | |||
p53 Antibody (2B2.68) X | sc-71817 X | 200 µg/0.1 ml | $322.00 |